INTRODUCTION
Muir-Torre syndrome (MTS) is a rare, hereditary, autosomal dominant cancer syndrome that is a variant of hereditary nonpolyposis colorectal carcinoma (HNPCC) or Lynch syndrome. 1 MTS is characterized by sebaceous neoplasms and HNPCC-associated malignancies such as colorectal, endometrial, and urothelial cancers. 1 The underlying genetic causes of MTS are mutations in or, more rarely, hypermethylation of DNA mismatch repair (MMR) genes, such as MLH1, MSH2, and MSH6. 1 Impaired MMR leads to errors in DNA repair during replication, which can cause microsatellite instability (MSI) and subsequent carcinogenesis. 2 Loss of MMR function leading to MSI has also been identified in a number of leukemias and lymphomas, 2,3 including mycosis fungoides (MF), a subtype of cutaneous T-cell lymphoma. Little is known about the molecular pathogenesis of MF, and unlike nodal lymphomas, specific chromosomal translocations have not been detected for MF. 4, 5 However, MSI might play a pivotal role in causing MF. In fact, there is evidence of MLH1 promoter hypermethylation and loss of MSH2 expression in MF. 2, 6 Although MSI has been identified in both MF and MTS, there is no known association between the 2 disorders to date. Herein, we describe a 65-year-old man with a 7-year history of MF who was later also diagnosed with MTS, and we suggest a possible association between MF and MTS.
CASE REPORT
In 2014, a 65-year-old white man sought treatment in a clinic at MD Anderson Cancer Center for MF. In 2009, he had presented to his local dermatologist with erythematous patches on his left thigh in a sun-shielded area (Fig 1) . Microscopic examination demonstrated an atypical lymphoid infiltrate with focal epidermotropism, and immunohistochemistry showed a CD4:CD8 ratio of 4:1 and loss of CD7 expression. These findings were all consistent with MF. He reported resolution of most of his lesions with clobetasol 0.05% ointment and of a recalcitrant patch with 4 Gy of radiation. His skin has remained free of MF involvement as of February 2017.
The patient's medical and social history was remarkable for a 52-pack per year smoker with an extensive personal and family history of HNPCC-associated malignancies (Tables I and II) , including small bowel and colon malignancies. Histopathologic examination of his cancerous small bowel following resection in 2014 showed high levels of MSI (MSI-H), defined as $ 40% altered markers. 2 This finding, together with his personal history of malignancies in the setting of a family history of endometrial, colon, and brain cancers, was suggestive of HNPCC.
Given the suspicion for HNPCC, he was referred for a genetics consultation. His small bowel and colon tumors were tested for MLH1, MSH2, MSH6, EPCAM, and PMS2 mutations via immunohistochemistry with both tumor sites exhibiting loss of staining of MSH2 and MSH6. MSI testing by polymerase chain reaction was not performed. Analysis of MSH2 revealed a duplication of exons 5-7, a mutation interpreted as a deleterious genetic variant, which lead to the diagnosis of HNPCC.
In 2016, the patient developed a papule on his left back that was biopsied and found to be a sebaceous adenoma, which was subsequently excised. Given his history of HNPCC and sebaceous neoplasms, as well as a Mayo MTS risk score of 4 (Table III) (Table IV) . 2, [6] [7] [8] The highly unstable MSI-H phenotype has also been found in 8% of MF cases, across all stages of disease. 2 In fact, MSI might be associated with disease progression in MF, as it has been more frequently detected in tumorstage MF (47%) than in early-stage MF (20%). 2 It is possible, though, that MSI in MF might occur during somatic cancer evolution in MF without being the disease driver. 9, 10 Loss of MLH1 expression causing MSI has been observed in MF (46%), 6 as has epigenetic silencing via hypermethylation of MMR gene-specific promoters. Aberrant methylation of the MLH1 promoter was detected in 64% of MF patients demonstrating MSI. 2 This hypermethylation has primarily been found in early-stage MF, suggesting that these epigenetic changes might arise early in the development of MF. 2 Thus, both loss of MLH1 expression and a specific mechanism for it, MLH1 transcriptional silencing, have been identified in MF.
Aside from MLH1, MSH2 might also be an important gene in MF. MSH2-knockout mice have been shown to develop predominantly T-cell lymphomas, 7 and loss of MSH2 expression was observed in 35% of MF cases. 6 Moreover, MSH2 is important in the repair of psoralen DNA interstrand crosslinks (ICLs). 8 If MSH2 defects are present in MF, then they might explain why some MF patients are particularly responsive to psoralen plus ultraviolet A (PUVA) or extracorporeal photopheresis (ECP). In contrast, MLH1-deficient cells have been found to be more resistant to psoralen ICLs, 8 which might explain why other MF patients fail to respond to PUVA or ECP. MSH2 deficiency is also associated with increased spontaneous and ultraviolet-induced skin carcinogenesis, 11 which would explain our patient's numerous skin cancers.
Despite the extreme rarity of both MF and MTS, our patient represents the third reported case of MF in a patient with MTS. 12, 13 Evidence of MSI-H and MLH1 promoter hypermethylation in both MF and MTS suggests a subset of MF cases might share the same molecular pathogenesis as cases of sebaceous neoplasms or gastrointestinal malignancies in MTS. A disease association notwithstanding, MLH1 and MSH2 might have clinical relevance in MF. Demethylating agents, such as azacitidine or decitabine, could theoretically treat MF by reversing MLH1 silencing. Furthermore, distinguishing MF lesions as MLH1or MSH2-deficient might help predict response to psoralen ICL-inducing therapies such as PUVA or ECP. 8 More work on the molecular pathogenesis of MF is needed to establish an association between MF and MTS. 
